Immunogenicity of Biosimilar Therapeutics in Drug Development (Q167968)

From geokb
Revision as of 14:05, 30 August 2024 by Sky (talk | contribs) (‎Changed label, description and/or aliases in en, and other parts: modified description with assistance from Llama 3.1)
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
  • Biosimilars
  • Immunogenicity
  • Bioanalytical Methods
  • Therapeutic Proteins
  • Dried Blood Spots
  • Erythropoietin Antibodies
  • Monoclonal Antibodies
  • Regulatory Guidelines
  • Biopharmaceuticals
  • Clinical Outcomes
Language Label Description Also known as
English
Immunogenicity of Biosimilar Therapeutics in Drug Development
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
  • Biosimilars
  • Immunogenicity
  • Bioanalytical Methods
  • Therapeutic Proteins
  • Dried Blood Spots
  • Erythropoietin Antibodies
  • Monoclonal Antibodies
  • Regulatory Guidelines
  • Biopharmaceuticals
  • Clinical Outcomes

Statements